Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty
Filter
Applied FilterClear all
TargetMol | Tags By Target
  • Trk receptor
    (65)
  • Apoptosis
    (11)
  • Autophagy
    (5)
  • c-Met/HGFR
    (5)
  • ALK
    (4)
  • Aurora Kinase
    (4)
  • FLT
    (4)
  • TAM Receptor
    (4)
  • VEGFR
    (4)
  • Others
    (7)
Filter
Search Result
Results for "

Trk receptor

" in TargetMol Product Catalog
  • Inhibitors & Agonists
    74
    TargetMol | Inhibitors_Agonists
  • Peptide Products
    1
    TargetMol | Peptide_Products
  • Inhibitory Antibodies
    1
    TargetMol | Inhibitory_Antibodies
  • PROTAC Products
    1
    TargetMol | PROTAC
  • Natural Products
    4
    TargetMol | Natural_Products
  • Recombinant Protein
    11
    TargetMol | Recombinant_Protein
  • Antibody Products
    5
    TargetMol | Antibody_Products
SP600125
Pyrazolanthrone, Nsc75890, JNK Inhibitor II, 1PMV
T3109129-56-6
SP600125 (JNK Inhibitor II) is a JNK inhibitor that inhibits JNK1, JNK2, and JNK3 (IC50=40 40 90 nM) with oral potency, reversibility, and ATP-competitive properties. SP600125 inhibits autophagy and induces apoptosis.
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Hot
Trk-IN-4
PF-6683324
T171691799788-94-5In house
Trk-IN-4 (PF-6683324) is a potent pan-Trk inhibitor with IC50 = 1.1~2.6 nM for TrkA TrkB TrkC and antinociceptive effects. It is also a selective type II PTK6 inhibitor with IC50 = 76 nM and has antitumor effects.
    6-8weeks
    Inquiry
    Amitriptyline hydrochloride
    Tryptizol, Domical, Annoyltin, Amitriptyline HCl
    T0678549-18-8
    Amitriptyline hydrochloride (Annoyltin) is the hydrochloride salt of the tricyclic dibenzocycloheptadiene amitriptyline with antidepressant and antinociceptive activities.
    • Inquiry Price
    Size
    QTY
    7,8-Dihydroxyflavone
    7,8-DHF
    T281638183-03-8
    7,8-Dihydroxyflavone (7,8-DHF) is a naturally-occurring flavone and exist in Tridax procumbens, Godmania aesculifolia, and primula tree leaves.
    • Inquiry Price
    Size
    QTY
    Entrectinib
    RXDX-101, NMS-E628
    T36781108743-60-7
    Entrectinib (RXDX-101) is a Trk, ROS1, and ALK inhibitor that inhibits TrkA, TrkB, TrkC, ROS1, and ALK (IC50=1 3 5 12 7 nM) with oral activity and blood-brain-barrier penetration. Entrectinib exhibits both antitumor and CNS activity.
    • Inquiry Price
    Size
    QTY
    Danusertib
    PHA-739358
    T2094827318-97-8
    Danusertib (PHA-739358) is a small-molecule 3-aminopyrazole derivative with potential antineoplastic activity. Danusertib binds to and inhibits the Aurora kinases, which may result in cell growth arrest and apoptosis in tumor cells in which Aurora kinases are overexpressed.
    • Inquiry Price
    Size
    QTY
    TargetMol | Inhibitor Sale
    Taletrectinib
    DS-6051b, AB-106
    T223181505515-69-4
    Taletrectinib (AB-106) is a new-generation selective inhibitor of ROS1 NTRK including ROS1,NTRK1,NTRK2 and NTRK3 with IC50 of 0.207 nM,0.622 nM,2.28 nM and 0.980 nM, respectively.
    • Inquiry Price
    Size
    QTY
    sitravatinib
    MGCD516, MG516
    T43491123837-84-2
    Sitravatinib (MGCD516) is an inhibitor targeting multiple RTKs involved in driving sarcoma cell growth, including c-Met, c-Kit, PDGFRα β, PDGFR, and Axl.
    • Inquiry Price
    Size
    QTY
    Milciclib
    PHA-848125
    T6081802539-81-7
    Milciclib (PHA-848125) (PHA-848125) is a potent, ATP-competitive CDK inhibitor for CDK2 with IC50 of 45 nM. It is >3-fold more selective for CDK2 than CDK1, 2, 4, 5, and 7. Phase 2.
    • Inquiry Price
    Size
    QTY
    gnf-5837
    GNF 5837
    T60971033769-28-6
    GNF-5837 is a specific, and orally bioavailable pan-TRK inhibitor for TrkA TrkB (IC50: 8 12 nM).
    • Inquiry Price
    Size
    QTY
    loxo-195
    BAY 2731954, (6RS)-LOXO-195
    T94961350884-56-8
    (6RS)-LOXO-195 (BAY 2731954) is a potent and selective Trk tyrosine kinase inhibitor.
    • Inquiry Price
    Size
    QTY
    TargetMol | Inhibitor Sale
    Tavilermide
    MIM-D3, MIMD3
    T17000263251-78-1
    Tavilermide (MIM-D3) is a selective TrkA agonist, a cyclic mimetic, which can be used to study dry keratoconjunctivitis and dry eye syndrome.
    • Inquiry Price
    6-8 weeks
    Size
    QTY
    PF-06273340
    PF-6273340, PF6273340, PF 6273340, PF 06273340
    T196491402438-74-7
    PF-06273340 is an effective, Selective, and Peripherally Restricted Pan-Trk inhibitor (IC50: Trk-A = 6 nM; Trk-B = 4 nM; Trk-C = 3 nM). PF-06273340 has low metabolic turnover in HLM and hHep is a good substrate for efflux transporters P-gp (ER = 35.7) and BCRP (ER = 4.0) and has moderate passive permeability (RRCK Papp = 5.4 × 10 6 cm s 1).
    • Inquiry Price
    10-14 weeks
    Size
    QTY
    Altiratinib
    DCC-2701
    T20541345847-93-9
    Altiratinib (DCC-2701)(DCC-2701) is a novel c-MET TIE-2 VEGFR inhibitor; effectively reduce tumor burden in vivo and block c-MET pTyr(1349)-mediated signaling, cell growth and migration as compared with an HGF antagonist in vitro.
    • Inquiry Price
    Size
    QTY
    TargetMol | Inhibitor Sale
    URMC-099
    T60571229582-33-5
    URMC-099 is an orally bioavailable, brain penetrant MLK inhibitor (IC50: 19 42 14 150 nM, for MLK1 MLK2 MLK3 DLK), and also inhibits LRRK2 activity (IC50: 11 nM).
    • Inquiry Price
    Size
    QTY
    PF-03814735
    T6936942487-16-3
    PF-03814735 is a novel, potent and reversible inhibitor of Aurora A B with IC50of 0.8 nM 5 nM, is less potent to Flt3, FAK, TrkA, and minimally active to Met and FGFR1. Phase 1.
      7-10 days
      Inquiry
      Type II TRK inhibitor 1
      T722892937543-72-9
      Type II TRK Inhibitor 1 is a potent inhibitor targeting multiple tropomyosin receptor kinase (TRK) fusion protein variants as well as the wild type. It demonstrates notable antiproliferative effects on Ba F3 cells expressing CD74-TRKA G667C and ETV6-TRKC G696C, with half-maximal inhibitory concentrations (IC50s) of 6 nM and 1.7 nM, respectively [1].
      • Inquiry Price
      8-10 weeks
      Size
      QTY
      TRK II-IN-1
      T730332904690-41-9
      TRK II-IN-1 is a potent type II inhibitor of tropomyosin receptor kinases (TRK), with IC50 values of 3.3, 6.4, 4.3, and 9.4 nM against TRKA, TRKB, TRKC, and the mutant TRKA G667C, respectively. It also exhibits IC50 values of 1.3 nM against FLT3, 9.9 nM against RET, and 71.1 nM against VEGFR2. TRK II-IN-1 primarily serves as a research tool for studying TRK-driven cancers [1].
      • Inquiry Price
      6-8 weeks
      Size
      QTY
      TRK-IN-23
      T789682924344-29-4
      TRK-IN-23 (compound 24b) is a potent, orally active TRK inhibitor with IC50s of 0.5 nM for TRKA, 9 nM for TRKC, 14 nM for TRKA G595R, 4.4 nM for TRKA F589L, and 4.8 nM for TRKA G667C. It induces apoptosis in Ba F3-TRKAG595R and Ba F3-TRKAG667C cells [1].
      • Inquiry Price
      6-8 weeks
      Size
      QTY
      TrkB-IN-1
      T790111609067-49-3
      TrkB-IN-1 is a potent, orally active agonist of the TrkB receptor, with favorable pharmacokinetic (PK) properties. It has been shown to reverse cognitive deficits in an Alzheimer's disease (AD) mouse model, thus serving as a valuable tool for Alzheimer's disease research [1].
      • Inquiry Price
      8-10 weeks
      Size
      QTY
      Protein kinase inhibitor 5
      T791252278204-94-5
      Protein kinase inhibitor 5 is a potent inhibitor of TRK-A, with an IC50 of 1.8 nM, and effectively suppresses cell viability [1].
      • Inquiry Price
      6-8 weeks
      Size
      QTY
      Protein kinase inhibitor 5 sulfate hydrate
      T79126
      Protein kinase inhibitor 5 sulfate hydrate, a potent TRK-A inhibitor, exhibits an IC50 of 1.8 nM and impairs cell viability [1].
      • Inquiry Price
      Size
      QTY
      TRK-IN-24
      T797062937544-01-7
      TRK-IN-24 (compound 10g) is a selective inhibitor of Trk receptors, effectively targeting TRKA, TRKC, and mutant forms TRKA G595R, TRKA G667C, and TRKA F589L, with corresponding IC50 values of 5.21, 4.51, 6.77, 1.42, and 6.13 nM. It demonstrates antitumor activity in BaF3-CD74-NTRK1 G595R and BaF3-CD74-NTRK1 G667C xenograft models and inhibits the proliferation of Ba F3 cells expressing single mutants SF, GK, and xDFG, with an IC50 range of 1.43-47.56 nM [1].
      • Inquiry Price
      8-10 weeks
      Size
      QTY
      Multi-kinase-IN-6
      T81740
      Multi-kinase-IN-6 (compound 10e) is a multikinase inhibitor that impedes the activity of TrkA, ALK2, c-KIT, EGFR, PIM1, CK2α, CHK1, and CDK2. It exhibits antiproliferative effects on MCF7, HCT116, and EKVX cancer cell lines with IC50s of 3.36 μM, 1.40 μM, and 3.49 μM, respectively. Additionally, Multi-kinase-IN-6 induces cell cycle arrest at the G1 S and G1 phases in MCF7 and HCT116 cells, respectively, and effectively triggers apoptosis [1].
      • Inquiry Price
      Size
      QTY